Suppr超能文献

用于局部给药的液体西罗莫司的临床前研究。

Pre-clinical investigation of liquid sirolimus for local drug delivery.

作者信息

Todd Meagan, Liu Linda B, Saul Justin M, Yazdani Saami K

机构信息

Department of Engineering, Wake Forest University, Winston-Salem, NC, United States.

Department of Chemical, Paper and Biomedical Engineering, Miami University, Oxford, OH, United States.

出版信息

Front Cardiovasc Med. 2023 Sep 15;10:1184816. doi: 10.3389/fcvm.2023.1184816. eCollection 2023.

Abstract

INTRODUCTION

Sirolimus is currently being explored as an alternative drug to paclitaxel for the treatment of peripheral artery disease (PAD). To date, sirolimus has only been used as drug coatings for stents and balloons and no studies have yet demonstrated the delivery of sirolimus in liquid form. The purpose of this pilot study was to investigate the feasibility of the delivery of liquid sirolimus into arterial segments in a benchtop peripheral artery bioreactor.

METHODS

The feasibility to deliver liquid therapy was first tested on four drug delivery devices using a fluorescently tagged liquid drug and an porcine artery benchtop model. The four devices included the Bullfrog micro-infusion device, ClearWay RX catheter, Occlusion perfusion catheter (OPC), and the targeted adjustable pharmaceutical administration system (TAPAS). Penetration of the fluorescently tagged drug was measured via microscopic imaging and quantification of the depth of drug penetration into all device-treated tissue. Based on the penetration outcome, we then selected a single device to deliver liquid sirolimus into the porcine artery model undergoing physiological flow and pressure conditions. The liquid sirolimus-treated arteries were collected from the bioreactor at 1- and 24-hour post-delivery and arterial drug retention analyzed by liquid chromatography-tandem mass spectrometry.

RESULTS

Fluorescent microscopy demonstrated that drug delivery with the OPC had greater drug penetration into the medial wall as compared to other devices (OPC: 234 ± 161 µm; TAPAS: 127 ± 68 µm; ClearWay: 118 ± 77 µm; Bullfrog: 2.12 ± 3.78 µm;  = 0.098). The results of the flow-circuit bench top model showed that the OPC device successfully delivered the liquid sirolimus at 1-hour (5.17 ± 4.48 ng/mg) and 24-hour (0.78 ± 0.55 ng/mg).

CONCLUSIONS

These results demonstrate for the first time the ability to deliver liquid sirolimus directly to the medial layer of an artery via a liquid delivery catheter.

摘要

引言

西罗莫司目前正作为紫杉醇的替代药物用于治疗外周动脉疾病(PAD)。迄今为止,西罗莫司仅被用作支架和球囊的药物涂层,尚无研究证明其以液体形式给药的情况。本初步研究的目的是探讨在台式外周动脉生物反应器中向西罗莫司液体给药至动脉段的可行性。

方法

首先使用荧光标记的液体药物和猪动脉台式模型,在四种给药装置上测试液体疗法给药的可行性。这四种装置包括牛蛙微量输注装置、ClearWay RX导管、闭塞灌注导管(OPC)和靶向可调药物给药系统(TAPAS)。通过显微镜成像和量化药物渗透到所有经装置处理组织中的深度,来测量荧光标记药物的渗透情况。基于渗透结果,我们随后选择单个装置,在生理血流和压力条件下,向西罗莫司液体给药至猪动脉模型。在给药后1小时和24小时从生物反应器中收集经液体西罗莫司处理的动脉,并通过液相色谱 - 串联质谱法分析动脉药物保留情况。

结果

荧光显微镜显示,与其他装置相比,使用OPC给药时药物向中膜壁的渗透更大(OPC:234±161μm;TAPAS:127±68μm;ClearWay:118±77μm;牛蛙:2.12±3.78μm;P = 0.098)。流动回路台式模型的结果表明,OPC装置在1小时(5.17±4.48ng/mg)和24小时(0.78±0.55ng/mg)成功给药液体西罗莫司。

结论

这些结果首次证明了通过液体给药导管将液体西罗莫司直接递送至动脉中层的能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58a5/10540618/fb15f4561700/fcvm-10-1184816-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验